What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

Description

Dr. Rachel Richesson discusses the key factors in using EHR data for endpoints and outcomes, emphasizing EHR data should be easy to collect, explicit, reproducible, and useful.

Speaker

Rachel Richesson, PhDHeadshot of Rachel Richesson
Professor of Learning Health Sciences, University of Michigan Medical School
Electronic Health Records Core Co-chair

 

Related

What Are the Challenges of Using Data Directly From the EHRs?

What Is A Computable Phenotype?

What Are the Benefits to Standardizing Phenotype Definition?

Using Electronic Health Record Data in Pragmatic Clinical Trials

What Do Endpoints and Outcomes Look Like in Pragmatic Trials?

What Do Endpoints and Outcomes Look Like in Pragmatic Trials?

Description

Endpoints and outcomes are different in pragmatic trials than in explanatory trials. In pragmatic trials, outcomes and endpoints should be meaningful to key stakeholders, easy to collect, and relying on routinely collected data. In explanatory trials, researchers are often looking at short-term surrogates or process measures and data are collected outside of the realm of routine care.

Speaker

Devon Check, PhD

Devon Check, PhD
Assistant Professor, Population Health Sciences
Duke University School of Medicine
Implementation Science Core Co-Chair

 

 

 

Related

What Are Endpoints And Outcomes?

How Do Data Sources Inform the Choice of Endpoints and Outcomes in Pragmatic Trials?

How Do Data Sources inform the Choice of Endpoints and Outcomes in Pragmatic Trials?

How Do Data Sources inform the Choice of Endpoints and Outcomes in Pragmatic Trials?

Description

Pragmatic clinical trials are often dealing with multiple sources of data from more than one health system, EHRs, and multiple payers claims databases. It can be a balancing act in terms of measurement and pragmatism. While patient-reported outcomes are more expensive, and less efficient, they are often the most salient outcomes from a stakeholder perspective, and therefore, important to collect in pragmatic clinical trials.

Speaker

Devon Check, PhD

Devon Check, PhD
Assistant Professor, Population Health Sciences
Duke University School of Medicine
Implementation Science Core Co-Chair

 

 

Related

What Are Endpoints And Outcomes?

What Do Endpoints And Outcomes Look Like in Pragmatic Trials?

What Are the Challenges of Using Data Directly From the EHRs?

What Are the Challenges of Using Data Directly From the EHRs?

Description

Dr. Rachel Richesson discusses the challenges of using data directly from the electronic health records (EHRs), including differences in systems different data coding and representation conventions.

Speaker

Rachel Richesson, PhDHeadshot of Rachel Richesson
Professor of Learning Health Sciences, University of Michigan Medical School
Electronic Health Records Core Co-chair

 

Related

What Is A Computable Phenotype?

What Are the Benefits to Standardizing Phenotype Definition?

What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

Using Electronic Health Record Data in Pragmatic Clinical Trials

What Are the Arguments For and Against the Stepped-Wedge Design?

What Are the Arguments For and Against the Stepped-Wedge Design?

Description

Dr. Liz Turner discusses arguments for and against using the stepped-wedge design when choosing the right cluster randomized trial in pragmatic research. Turner recommends if possible, using a parallel design, but if a stepped-wedge design is necessary, plan for time effects in design and analysis.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Types of CRT Designs?

What Is An Example of How to Choose a Study Design?

What Is the Intraclass Correlation Coefficient?

What Is the Intraclass Correlation Coefficient?

Description

Dr. Liz Turner discusses the Intraclass Correlation Coefficient (ICC), which is the measure between-cluster outcome variability relative to the overall variability in the system.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

Related

What Are the Reasons to Randomize Clusters Instead of Individuals?

What Is Outcome Clustering, and How Can It Affect a Trial?

How Does Clustering Affect Power and Detectable Difference?

How Do You Estimate the Degree of Clustering for Outcomes?

What Is A Computable Phenotype?

What Is A Computable Phenotype?

Description

Dr. Rachel Richesson discusses the specifications of defining computable phenotypes. This term is often used to identify patients for a study or to identify conditions that serve as outcomes of various studies.

Speaker

Rachel Richesson, PhDHeadshot of Rachel Richesson
Professor of Learning Health Sciences, University of Michigan Medical School
Electronic Health Records Core Co-chair

 

Related

What Are the Challenges of Using Data Directly From the EHRs?

What Are the Benefits to Standardizing Phenotype Definition?

What Are the Key Factors in Using EHR Data for Endpoints and Outcomes?

Using Electronic Health Record Data in Pragmatic Clinical Trials

What Is An Example of How to Choose a Study Design?

What Is An Example of How to Choose a Study Design?

Description

Dr. Liz Turner provides a framework for choosing a study design by discussing the design of SPOT, STOP CRC, LIRE, and OPTIMUM, which are all NIH Collaboratory Trials within the Collaboratory. Turner shares similarities and differences regarding the design of these trials to aid researchers in making decisions about the most effective study design for their trial.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Types of CRT Designs?

What Are the Arguments For and Against the Stepped-Wedge Design?

What Are Endpoints and Outcomes?

What Are Endpoints and Outcomes?

Description

Dr. Devon Check discusses the difference between endpoints and outcomes in pragmatic clinical trials with endpoints referring to change in a measured variable and outcome describing the variable itself.

Speaker

Devon Check, PhD

Devon Check, PhD
Assistant Professor, Population Health Sciences
Duke University School of Medicine
Implementation Science Core Co-Chair

 

Related

What Do Endpoints And Outcomes Look Like in Pragmatic Trials?

How Do Data Sources Inform the Choice of Endpoints and Outcomes in Pragmatic Trials?

 

What Is Outcome Clustering, and How Can It Affect a Trial?

What Is Outcome Clustering, and How Can It Affect a Trial?

Description

In this video, Dr. Liz Turner demystifies the notions of outcome clustering, which for a pragmatic trial might mean clustering at the level of a clinic and an intervention.

Speaker

Liz Turner, PhD
Associate Professor, Biostatistics and Bioinformatics and Global Health
Biostatistics and Study Design Core Co-Chair

 

 

Related

What Are the Reasons to Randomize Clusters Instead of Individuals?

What Is the Intraclass Correlation Coefficient?

How Does Clustering Affect Power and Detectable Difference?

How Do You Estimate the Degree of Clustering for Outcomes?